Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

Journal of Immunology

Volumn 174, Issue 3, 2005, Pages 1580-1586

  Agadjanyan, Michael G ^a   Ghochikyan, Anahit ^a   Petrushina, Irina ^b   Vasilevko, Vitaly ^b   Movsesyan, Nina ^a   Mkrtichyan, Mikayel ^a   Saing, Tommy ^b   Cribbs, David H ^b,c  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANTIBODY; EPITOPE; HLA DR3 ANTIGEN; PROTEIN PADRE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 12444268257     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.3.1580     Document Type: Article

References (61)

1. Price, D. L., and S. S. Sisodia. 1994. Cellular and molecular biology of Alzheimer's disease and animal models. Annu. Rev. Med. 45:435.
2. Selkoe, D. 1991. Amyloid protein and Alzheimer's disease. Sci Am. 265:68.
3. Selkoe, D. J. 1994. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53:438.
4. Esler, W. P., and M. S. Wolfe. 2001. A portrait of Alzheimer secretases-new features and familiar faces. Science 293:1449.
5. Hardy, J. A., and G. A. Higgins. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184.
6. Hardy, J., and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353.
7. Helmuth, L. 2002. New therapies: new Alzheimer's treatments that may ease the mind. Science 297:1260.
8. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173.
9. Schenk, D. 2002. Opinion: amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3:824.
10. Morgan, D., D. M. Diamond, P. E. Gottschall, K. E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, et al. 2000. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982.
11. Janus, C., M., A. Chishti, and D. Westaway. 2000. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta 1502:63.
12. Chen, G., K. S. Chen, J. Knox, J. Inglis, A. Bernard, S. J. Martin, A. Justice, L. McConlogue, D. Games, S. B. Freedman, et al. 2000. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975.
13. Bard, F., C. Cannon, R. Barbour, R. L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, et al. 2000. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916.
14. DeMattos, R. B., K. R. Bales, D. J. Cummins, J. C. Dodart, S. M. Paul, and D. M. Holtzman. 2001. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98:8850.
15. Dodart, J. C., K. R. Bales, K. S. Gannon, S. J. Greene, R. B. DeMattos, C. Mathis, C. A. DeLong, S. Wu, X. Wu, D. M. Holtzman, et al. 2002. Immunization reverse memory deficits without reducing brain Ab burden in Alzheimer's disease model. Nat. Neurosci. 5:452.
16. Pfeifer, M., S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P. M. Mathews, and M. Jucker. 2002. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298:1379.
17. Steinberg, D. 2002. Companies halt first Alzheimer's vaccine trial. Scientist 16:22.
18. Birmingham, K., and S. Frantz. 2002. Set back Alzheimer vaccine studies. Nat. Med. 8:199.
19. Hock, C., U. Konietzko, J. R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, et al. 2003. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547.
20. Orgogozo, J. M., S. Gilman, J. F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46.
21. Ferrer, I., M. Boada Rovira, M. L. Sanchez Guerra, M. J. Rey, and F. Costa-Jussa. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 14:11.
22. Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9:448.
23. Broytman, O., and J. S. Malter. 2004. Anti-Aβ: the good, the bad, and the unforeseen. J. Neurosci. Res. 75:301.
24. Solomon, B., R. Koppel, E. Hanan, and T. Katzav. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Nat. Acad. Sci. USA 93:452.
25. Solomon, B., R. Koppel, D. Frankel, and E. Hanan-Aharon. 1997. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Nat. Acad. Sci. USA 94:4109.
26. Frenkel, D., M. Balass, E. Katchalski-Katzir, and B. Solomon. 1999. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95:136.
27. Bard, F., R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, et al. 2003. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100:2023.
28. Town, T., J. Tan, N. Sansone, D. Obregon, T. Klein, and M. Mullan. 2001. Characterization of murine immunoglobulin G antibodies against human amyloid-β 1-42. Neurosci. Lett. 307:101.
29. Dickey, C. A., D. G. Morgan, S. Kudchodkar, D. B. Weiner, Y. Bai, C. Cao, M. N. Gordon, and K. E. Ugen. 2001. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide. DNA Cell Biol. 20:723.
30. Lemere, C. A., R. Maron, D. J. Selkoe, and H. L. Weiner. 2001. Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20:705.
31. Lemere, C. A., R. Maron, E. T. Spooner, T. J. Grenfell, C. Mori, R. Desai, W. W. Hancock, H. L. Weiner, and D. J. Selkoe. 2000. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920:328.
32. Cribbs, D. H., A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C. W. Cotman, et al. 2003. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol. 15:505.
33. Petrushina, I., M. Tran, N. Sadzikava, A. Ghochikyan, V. Vasilevko, M. G. Agadjanyan, and D. H. Cribbs. 2003. Importance of IgG2c isotype in the immune response to β-amyloid in amyloid precursor protein/transgenic mice. Neurosci. Lett. 338:5.
34. McLaurin, J., R. Cecal, M. E. Kierstead, X. Tian, A. L. Phinney, M. Manea, J. E. French, M. H. Lambermon, A. A. Darabie, M. E. Brown, et al. 2002. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8:1263.
35. Miller, D. L., J. R. Currie, P. D. Mehta, A. Potempska, Y. W. Hwang, and J. Wegiel. 2003. Humoral immune response to fibrillar β-amyloid peptide. Biochemistry 42:11682.
36. del Guercio, M. F., J. Alexander, R. T. Kubo, T. Arrhenius, A. Maewal, E. Appella, S. L. Hoffman, T. Jones, D. Valmori, K. Sakaguchi, et al. 1997. Potent immunogenic short linear peptide constructs composed of B cell epitopes and pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15:441.
37. Alexander, J., M. F. del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, and A. Sette. 2000. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:1625.
38. La Rosa, C., Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al. 2002. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100:3681.
39. Wei, W. Z., S. Ratner, T. Shibuya, G. Yoo, and A. Jani. 2001. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. J. Immunol. Methods 258:141.
40. Weber, J. S., F. L. Hua, L. Spears, V. Many, C. Kuniyoshi, and E. Celis. 1999. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22:431.
41. Alexander, J., J. Fikes, S. Hoffman, E. Franke, J. Sacci, E. Appella, F. V. Chisari, L. G. Guidotti, R. W. Chesnut, B. Livingston, et al. 1998. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18:79.
42. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, and A. Sette. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
43. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
44. Tam, J. P. 1988. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 5:5409.
45. Chai, S. K., P. Clavijo, J. P. Tam, and F. Zavala. 1992. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J. Immunol. 149:2385.
46. Ghochikyan, A., V. Vasilevko, I. Petrushina, N. Movsesyan, D. Babikyan, W. Tian, N. Sadzikava, T. M. Ross, E. Head, D. H. Cribbs, et al. 2003. Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur. J. Immunol. 33:3232.
47. Agadjanyan, M. G., N. N. Trivedi, S. Kudchodkar, M. Bennett, W. Levine, A. Lin, J. Boyer, D. Levy, K. E. Ugen, J. J. Kim, et al. 1997. An HIV type 2 DNA vaccines induces cross-reactive immune responses against HIV type 2 and SIV. AIDS Res. Hum. Retroviruses 13:1561.
48. + IFN-γ and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol. 168:6189.
49. Finkelman, F. D., J. Holmes, I. M. Katona, J. F. Urban, M. P. Beckmann, L. S. Park, K. A. Schooley, R. L. Coffman, T. R. Mossmann, and W. E. Paul. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:303.
50. Evans, D. A., H. H. Funkenstein, M. S. Albert, P. A. Scherr, N. R. Cook, M. J. Chown, L. E. Hebert, C. H. Hennekens, and J. O. Taylor. 1989. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. J. Am. Med. Assoc. 262:2551.
51. Morgan, D. 2001. The intersection of Alzheimer's disease and typical aging. Neurobiol. Aging 1:159.
52. Helmuth, L. 2003. Detangling Alzheimer's disease: new insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. Sci. Aging Knowledge Environ. 2003:oa2.
53. Greenberg, S. M., B. J. Bacskai, and B. T. Hyman. 2003. Alzheimer disease's double-edged vaccine. Nat. Med. 9:389.
54. Hock, C., U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R. C. Von Rotz, G. Davey, E. Moritz, and R. M. Nitsch. 2002. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8:1270.
55. Weiner, H. L., and D. J. Selkoe. 2002. Inflammation and therapeutic vaccination in CNS diseases. Nature 420:879.
56. Monsonego, A., and H. L. Weiner. 2003. Immunotherapeutic approaches to Alzheimer's disease. Science 302:834.
57. Monsonego, A., V. Zota, A. Karni, J. I. Krieger, A. Bar-Or, G. Bitan, A. E. Budson, R. Sperling, D. J. Selkoe, and H. L. Weiner. 2003. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112:415.
58. + T cells: induction of type 2 cytokine production by T1/ST2 crosslinking. J. Immunol. 166:3143.
59. Xu, D., W. L. Chan, B. P. Leung, D. Hunter, K. Schulz, R. W. Carter, I. B. McInnes, J. H. Robinson, and F. Y. Liew. 1998. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J. Exp. Med. 188:1485.
60. Townsend, M. J., P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST1 in developing primary T helper cell type 2 responses. J. Exp. Med. 191:1069.
61. Hilbich, C., B. Kisters-Woike, J. Reed, C. L. Masters, and K. Beyreuther. 1991. Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4. Eur. J. Biochem. 201:61.